New Class of Anticancer Chemotherapy Agents

Back to all technologies
Download as PDF
2017-GHOS-67971
According to the National Cancer Institute, approximately 40 percent of people will be diagnosed with cancer in their lifetime and worldwide number of diagnostics are predicted to increase nearly 50 percent by 2030. Nearly 2 percent of all men and 1.5 percent of all women are killed each year by cancer. Cancer is simply described as continuous and uncontrolled division of cells leading to tumors. With the increase in cancer cases worldwide and the lack of a consistent treatment, new development are still needed in the field.

Researchers at Purdue University have synthesized a number of natural products that inhibit cell splicing. These herboxidiene derivatives inhibit cell division through its interactions with the proteins responsible for pre-mRNA splicing. This technology shows potential for use in a variety of select human cancers with increased functionality and consistent stability and potency.

Advantages:
-Stable and potent
-Appropriate drug functionalities for conjugates

Potential Applications:
-Pharmaceuticals
-Anticancer, chemotherapy drugs
Jan 24, 2020
NATL-Patent
United States
(None)
(None)

Jul 26, 2018
PCT-Patent
WO
(None)
(None)

Jul 26, 2017
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org